International Journal of Molecular Medical Science, 2024, Vol.14, No.4, 252-263 http://medscipublisher.com/index.php/ijmms 262 Hanafy A., Schoch S., and Lamprecht A., 2020, CRISPR/Cas9 delivery potentials in Alzheimer's disease management: a mini review, Pharmaceutics, 12(9): 108. https://doi.org/10.3390/pharmaceutics12090801 PMid:32854251 PMCid:PMC7559557 Haridhasapavalan K., Borgohain M., Dey C., Saha B., Narayan G., Kumar S., and Thummer R., 2019, An insight into non-integrative gene delivery approaches to generate transgene-free induced pluripotent stem cells, Gene, 686: 146-159. https://doi.org/10.1016/j.gene.2018.11.069 PMid:30472380 Honig L., 2018, Gene therapy in alzheimer disease-it may be feasible, but will it be beneficial?, JAMA Neurology, 75(7): 791-793. https://doi.org/10.1001/jamaneurol.2017.4029 PMid:29582049 Kent S., Spires-Jones T., and Durrant C., 2020, The physiological roles of tau and Aβ: implications for Alzheimer's disease pathology and therapeutics, Acta Neuropathologica, 140: 417-447. https://doi.org/10.1007/s00401-020-02196-w PMid:32728795 PMCid:PMC7498448 Komatsu Y., Takeuchi D., Tokunaga T., Sakurai H., Makino A., Honda T., Ikeda Y., and Tomonaga K., 2019, RNA virus-based episomal vector with a fail-safe switch facilitating efficient genetic modification and differentiation of iPSCs, Molecular Therapy Methods and Clinical Development, 14: 47-55. https://doi.org/10.1016/j.omtm.2019.05.010 PMid:31309127 PMCid:PMC6606997 Kumar P., and Woon-Khiong C., 2011, Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications, Current Gene Therapy, 11(2): 144-153. https://doi.org/10.2174/156652311794940782 PMid:21291355 Lacour M., Quenez O., Rovelet-Lecrux A., Salomon B., Rousseau S., Richard A., Quillard‐Muraine M., Pasquier F., Rollin-Sillaire A., Martinaud O., Zaréa A., Sayette V., Boutoleau-Bretonnière C., Etcharry-Bouyx F., Chauviré V., Sarazin M., Ber I., Epelbaum S., Jonveaux T., Rouaud O., Ceccaldi M., Godefroy O., Formaglio M., Croisile B., Auriacombe S., Magnin E., Sauvée M., Marelli C., Gabelle A., Pariente J., Paquet C., Boland A., Deleuze J., Campion D., Hannequin D., Nicolas G., and Wallon D., 2019, Causative mutations and genetic risk factors in sporadic early onset alzheimer's disease before 51 years, Journal of Alzheimer's Disease, 71(1): 227-243. https://doi.org/10.3233/JAD-190193 PMid:31381512 LaFerla F., and Green K., 2012, Animal models of Alzheimer disease, Cold Spring Harbor Perspectives in Medicine, 2: 11. https://doi.org/10.1101/cshperspect.a006320 PMid:23002015 PMCid:PMC3543097 Li J.H., and Li J., 2024, Gene editing for organ transplants: evaluating the impact of CRISPR/Cas9 on immunogenicity and organ longevity in pigs, International Journal of Clinical Case Reports, 14(2): 94-106. https://doi.org/10.5376/ijccr.2024.14.0012 Loera-Valencia R., Piras A., Ismail M., Manchanda S., Eyjólfsdóttir H., Saido T., Johansson J., Eriksdotter M., Winblad B., and Nilsson P., 2018, Targeting Alzheimer's disease with gene and cell therapies, Journal of Internal Medicine, 284: 2-36. https://doi.org/10.1111/joim.12759 PMid:29582495 Lu L., Yu X., Cai Y., Sun M., and Yang H., 2021, Application of CRISPR/Cas9 in Alzheimer's disease, Frontiers in Neuroscience, 15: 803894. https://doi.org/10.3389/fnins.2021.803894 PMid:34992519 PMCid:PMC8724030 Owens L., Benedetto A., Dawson N., Gaffney C., and Parkin E., 2021, Gene therapy-mediated enhancement of protective protein expression for the treatment of Alzheimer's disease, Brain Research, 1753: 147264. https://doi.org/10.1016/j.brainres.2020.147264 PMid:33422539 Paquet D., Kwart D., Chen A., Sproul A., Jacob S., Teo S., Olsen K., Gregg A., Noggle S., and Tessier-Lavigne M., 2016, Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9, Nature, 533: 125-129. https://doi.org/10.1038/nature17664 PMid:27120160 Ralph G., Binley K., Wong L., Azzouz M., and Mazarakis N., 2006, Gene therapy for neurodegenerative and ocular diseases using lentiviral vectors, Clinical Science, 110(1): 37-46. https://doi.org/10.1042/CS20050158 PMid:16336203 Roda A., Serra-Mir G., Montoliu-Gaya L., Tiessler L., and Villegas S., 2022, Amyloid-beta peptide and tau protein crosstalk in Alzheimer's disease, Neural Regeneration Research, 17: 1666-1674. https://doi.org/10.4103/1673-5374.332127 PMid:35017413 PMCid:PMC8820696
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==